Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020473 (hyperlipidemia)
 15,891 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Hypertensive patients with hyperlipidemia are at high risk to develop coronary heart disease (CHD). Chemotherapeutic correction of hyperlipidemia seems most reliable modality to prevent CHD. Hypolipidemic effect and tolerance of leskol (fluvastatin) in dietotherapy-resistant hypercholesterolemia were studied in 74 patients with essential hypertension treated with hypotensive drugs. The patients were included in a multicenter trial. A 12-week course reduced total cholesterol level under 6.2 mmol/l in 59% of the patients, under 5.2 mmol/l in 29% of them. LDLP cholesterol lowered to 3.5% in 34% of the patients. Mean apo B diminished by 23%. There was a 27% decrease in the proportion of atherogenic fraction apo B to antiatherogenic fraction of transport proteins apo A-I. Leskol is well tolerated and effective against hypercholesterolemia, it is safe in relation to side effects and blood biochemistry.
 ...
PMID:[The hypolipidemic effect of and tolerance for Lescol in treating hypercholesterolemia in hypertension patients (an analysis of the data from a multicenter study)]. 770 57

The hypocholesterolemic action of long-acting garlic powder tablets Allicor was investigated in a double-blind placebo-controlled study in men with mild hypercholesterolemia. Group 1 received allicor in a daily dose 600 mg, group 2 received placebo. The results show that allicor lowers total cholesterol, LDLP cholesterol, raises HDLP cholesterol and therefore can be recommended for correction of lipid content in patients with moderate hyperlipidemia.
 ...
PMID:[Correction of hyperlipidemia with Allicor]. 1516 12

It is well known now that hypolipidemic therapy is able to inhibit development of atherosclerosis. This decreases the rate of coronary complications. However, the problem of adequate pharmacotherapy duration has not been solved yet, as long-term treatment may provoke side effects. This study compared efficacy of hyperlipidemia (HLE) correction by long-term hypolipidemic diet (HD) and pharmacotherapy (PT) in patients with ischemic heart disease (IHD). 93 HLE patients with IHD aged 50-65 years entered the study. Enduracin used for 16-24 weeks (Endurance Products Company, USA) in a dose 1500 mg/day has reduced cholesterol by 15.7%, low density lipoproteins--by 19.2%, triglycerides--by 26%. High density lipoproteins rose by 15.7%. Besafibrat (Germany) in a dose 600 mg/day is indicated for patients with isolated hypertriglyceridemia (reduced triglycerides by 41.2%). Enduracin is indicated for patients with moderate levels of atherogenic serum lipids in isolated and combined HLE if fibrates are contraindicated. Diet lowered LDLP and VLDLP insignificantly and did not change HDLP. Prolongation of diet did not enhance the effect this allowing using diet therapy as background treatment.
 ...
PMID:[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease]. 1523 46